https://www.selleckchem.com/pr....oducts/Vorinostat-sa
We investigated the effects of the SGLT2 inhibitor luseogliflozin on blood and urinary glucose and body weight. Luseogliflozin 2.5 mg was administered once daily for 24 weeks to 30 outpatients with type 2 diabetes. Urinary glucose concentration, continuous glucose monitoring values, HbA1c, fasting glucose, and body weight were evaluated. Correlations with urinary glucose, subcutaneous/visceral fat mass, insulin, EPA/AA ratio, plasma free fatty acids, ghrelin, blood ketones, plasma 1,5-anhydro-D-glucitol were evaluated. Urinary g
Curtir
Comentario
Compartilhar
